Makary's FDA Resignation Creates Opportunity for Pro-Life Action on Abortion Drugs
Source: Jordan Boyd. "As Makary Exits, Pro-Lifers Await Movement On Abortion Drugs." May 13, 2026. thefederalist.com
The Gist
The author argues that the resignation of FDA Commissioner Marty Makary is good news for pro-life advocates because he failed to properly regulate dangerous abortion pills. Now there's a chance to get someone in charge who will actually protect women by restricting these drugs.
Conclusion
FDA Commissioner Marty Makary's resignation represents a crucial opportunity for the Trump administration to appoint a pro-life replacement who will take decisive action against abortion drugs, particularly mifepristone
Premises
- Makary failed to adequately review mifepristone despite evidence showing an 11% maternal injury rate that is 22 times higher than the drug's label states
- Under Makary's leadership, the FDA continued Biden-era policies allowing mail-order abortion pills without proper medical oversight
- Makary approved a generic version of the abortion pill despite safety concerns and slow-walked promised reviews of existing abortion drugs
- Pro-life groups and Republican politicians had been calling for Makary's removal for months due to his handling of abortion drug policies
- The current acting commissioner Kyle Diamantas previously represented Planned Parenthood, making him unsuitable for pro-life objectives
- Majority polling shows voters want the FDA to protect women from dangers of abortion pills
Assumptions
- Abortion drugs pose significant safety risks that current FDA oversight fails to address
- Mail-order abortion pills enable abuse and circumvent state pro-life laws
- The FDA has the authority and obligation to restrict or ban abortion drugs based on safety concerns
- A pro-life FDA commissioner would be more effective at protecting women and enforcing safety regulations
- The Trump administration should prioritize pro-life policy objectives at the FDA